CorMedix Inc. CRMD
5.27 USD +0.19 (+3.74%)
Regular-session close
5.32 +0.05 +0.95%
After hours · Nov 20, 7:29 PM ET
4.95 Day range 5.32
4.50 52-week range 12.73
- YTD
- -54.69%
- 1 year
- -45.78%
News
benzinga.com Deal Dispatch: Morgan Stanley Buys Vinyl Equity, Fox Completes Roku Acquisition, Children's Place Files for Chapter 11 Major M&A deals this week include: CorMedix buys Heron for $145M and Craveworthy Brands buys New England Authentic Eats.benzinga.com Oppenheimer Reiterates Outperform on Cormedix, Lowers Price Target to $13 Oppenheimer analyst Les Sulewski reiterates Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $15 to $13.
benzinga.com RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $14 RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $15 to $14.
zacks.com CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates CorMedix beats Q3 estimates, but DefenCath pricing pressure hurts sales. Rezzayo progress and the planned Heron acquisition shape its 2027 outlook.
seekingalpha.com CorMedix Inc. (CRMD) Q3 2026 Earnings Call Transcript CorMedix Inc. (CRMD) Q3 2026 Earnings Call Transcript
marketbeat.com What CorMedix (CRMD) Said on Its Q3 Earnings Call CorMedix NASDAQ: CRMD reported lower third-quarter revenue as its DefenCath product entered a new reimbursement period, while management outlined plans to acquire substantially all of Heron…
zacks.com CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates CorMedix (CRMD) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.57 per share a year ago.
benzinga.com Cormedix Q3 2026 Earnings Call Transcript Cormedix (NASDAQ:CRMD) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com Cormedix Q3 EPS $(0.19) Misses $(0.10) Estimate, Sales $54.519M Beat $53.227M Estimate Cormedix (NASDAQ:CRMD) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.10) by 90 percent. This is a 133.33 percent decrease over earnings of $0.57…
benzinga.com Cormedix Affirms FY2026 Sales Guidance of $325.000M-$345.000M vs $337.061M Est Cormedix (NASDAQ:CRMD) affirms FY2026 sales outlook from $325.000 million-$345.000 million to $325.000 million-$345.000 million vs $337.061 million estimate.
globenewswire.com Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update ‒ Recently announced acquisition of assets of Heron Therapeutics – ‒ Q3 2026 consolidated revenue of $54.5 million ‒ ‒ Q3 2026 net loss of $14.7 million ; Adjusted EBITDA of $3.1 million ‒ ‒ Company…benzinga.com RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $15 RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises the price target from $14 to $15.
zacks.com CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio CorMedix is set to acquire HRTX's commercial assets for $223 million upfront, adding four products, expanding its hospital reach and targeting significant cost synergies.
marketbeat.com CorMedix to Acquire Heron Assets, Adding Four Products and Targeting Up to $60 Million in Savings CorMedix NASDAQ: CRMD has agreed to acquire substantially all of Heron Therapeutics' assets, adding four commercial products and a development agreement to its portfolio of medicines used in…benzinga.com Needham Maintains Buy on Cormedix, Raises Price Target to $14 Needham analyst Serge Belanger maintains Cormedix (NASDAQ:CRMD) with a Buy and raises the price target from $12 to $14.
benzinga.com CorMedix Bolsters Hospital Pipeline via Heron Therapeutics Asset Deal CorMedix Therapeutics (NASDAQ:CRMD) on Monday said it will acquire substantially all assets and assume certain liabilities of Heron Therapeutics, Inc. (NASDAQ:HRTX) in an upfront transaction valued…
benzinga.com CorMedix Bolsters Hospital Pipeline via Heron Therapeutics Asset Deal CorMedix acquires Heron Therapeutics assets for $222.6 million upfront, adding four commercial hospital therapies to expand its acute care reach.benzinga.com CorMedix To Acquire Heron Therapeutics Assets For $145M Cash, Stock, And Potential Earn-Out Payments Adds four commercial-stage products — ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL® — to CorMedix's hospital- and acute-care-focused commercial platformUpfront consideration consisting of $145 million…
globenewswire.com CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care Adds four commercial-stage products — ZYNRELEF ® , APONVIE ® , CINVANTI ® and SUSTOL ® — to CorMedix's hospital- and acute-care-focused commercial platform Upfront consideration consisting of $145…
globenewswire.com CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026 PARSIPPANY, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the third quarter ended September 30, 2026,…
zacks.com Earnings Preview: CorMedix (CRMD) Q3 Earnings Expected to Decline CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.benzinga.com Needham Maintains Buy on Cormedix, Lowers Price Target to $12 Needham analyst Serge Belanger maintains Cormedix (NASDAQ:CRMD) with a Buy and lowers the price target from $15 to $12.
benzinga.com CorMedix Reaffirms FY26 Total Sales Guidance Of $325M-$345M; Anticipates That The DefenCath Add-On Will Decline Sequentially In Q2 2027, With A QoQ Increase In Q3 And/Or Q4 CorMedix announces unaudited cash and cash equivalents on hand as of September 30, 2026 of approximately $355 million. CorMedix reaffirms its August 2026 total revenue guidance of between $325…
globenewswire.com CorMedix Therapeutics Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash Position PARSIPPANY, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today provided a business update in advance of a conference call expected to be held on November 12, 2026 to…
defenseworld.net CorMedix (NASDAQ:CRMD) vs. MediciNova (NASDAQ:MNOV) Financial Analysis CorMedix (NASDAQ: CRMD - Get Free Report) and MediciNova (NASDAQ: MNOV - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two…
globenewswire.com Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases PARSIPPANY, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New…
prnewswire.com Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced…
zacks.com CRMD vs. PRTA: Which Stock Should Value Investors Buy Now? Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both CorMedix (CRMD) and Prothena (PRTA). But which of these two stocks offers value investors a better…
zacks.com Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet The consensus price target hints at a 67.7% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings…
globenewswire.com CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference PARSIPPANY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for…
zacks.com CorMedix (CRMD) Upgraded to Buy: Here's Why CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Trade The consensus price target hints at a 66% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate…
